Skip to main content
TipRanks
Go Ultimate75% OFF

IRLAB Therapeutics AB Class A (0GFH) AI Stock Analysis

0 Followers
GB:0GFH

IRLAB Therapeutics AB Class A

(LSE:0GFH)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improved Balance Sheet LeverageThe sharp reduction in debt-to-equity indicates materially lower financial strain than in prior years and gives IRLAB a stronger solvency position. This improvement can preserve flexibility for continued research spending and reduce the balance-sheet burden while clinical programs advance.
Negative Factors
Persistent UnprofitabilityThe company has not re-established a stable earnings base after losing profitability, and negative gross profit means current revenue does not cover direct costs. Continued losses can erode equity, constrain investment choices, and keep profitability dependent on successful development outcomes.

IRLAB Therapeutics AB Class A Business Overview & Revenue Model

Company Description

IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat,...

IRLAB Therapeutics AB Class A Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0GFH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SANIONSE:SANION77OutperformSEK 1.63B8.8029.71%―24.98%-31.44%
SE:BIOA.BSE:BIOA.B65NeutralSEK 27.05B256.135.18%0.70%-46.09%-90.13%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ALZCURSE:ALZCUR49NeutralSEK 852.21M10.30105.09%―――
SE:SYNACTSE:SYNACT43NeutralSEK 763.39M-7.26-60.58%――14.35%
SE:ALZSE:ALZ36UnderperformSEK 97.19M-1.82-15.44%―-100.00%40.79%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%SE:ALZSE:ALZCURSE:BIOA.BSE:SYNACTSE:SANIONDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0GFH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ALZAlzinova AB0.31-1.07-77.69%
SE:ALZCURAlzeCure Pharma AB6.184.41249.35%
SE:BIOA.BBioArctic AB Class B304.8023.878.50%
SE:SYNACTSynAct Pharma AB13.58-7.27-34.87%
SE:SANIONSaniona AB11.79-5.39-31.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.